Definium Therapeutics Inc (DFTX) is trading up at $36.00 (+1.44%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$33.0M | −$93.9M | −$66.3M | −$93.9M | −$103.9M | −$166.3M |
| Net income | −$33.9M | −$93.0M | −$56.8M | −$95.7M | −$108.7M | −$183.8M |
| EPS (diluted) | −$0.13 | −$3.40 | −$1.84 | −$2.44 | −$1.54 | −$2.06 |
| Balance sheet | ||||||
| Cash and equivalents | $80.1M | $133.5M | $142.1M | $99.7M | $273.7M | $257.8M |
| Total assets | $81.5M | $164.0M | $170.0M | $124.5M | $302.2M | $440.1M |
| Total liabilities | $5.65M | $12.3M | $19.1M | $46.4M | $60.7M | $107.8M |
| Long-term debt | — | — | — | $14.1M | $21.9M | $40.6M |
| Shareholders' equity | $75.9M | $151.7M | $150.9M | $78.1M | $241.4M | $332.3M |
| Cash flow | ||||||
| Operating cash flow | −$23.6M | −$45.8M | −$50.1M | −$64.4M | −$79.1M | −$131.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$24.8M | −$32.5M | −$32.2M | −$40.9M | −$45.7M | −$47.6M | −$59.2M | −$75.1M |
| Net income | −$13.7M | −$34.7M | −$23.3M | −$42.7M | −$67.3M | −$50.4M | −$77.1M | −$159.0M |
| EPS (diluted) | −$0.27 | $0.13 | −$0.35 | −$0.50 | −$0.78 | −$0.43 | −$0.71 | −$1.44 |
| Balance sheet | ||||||||
| Cash and equivalents | $295.3M | $273.7M | $82.9M | $33.4M | $20.0M | $257.8M | $262.5M | $655.3M |
| Total assets | $319.8M | $302.2M | $275.3M | $265.1M | $236.9M | $440.1M | $401.3M | $1.11B |
| Total liabilities | $57.6M | $60.7M | $52.5M | $79.7M | $106.3M | $107.8M | $122.4M | $194.2M |
| Long-term debt | $24.3M | $21.9M | $22.0M | $41.2M | $40.4M | $40.6M | $40.8M | $36.5M |
| Shareholders' equity | $262.2M | $241.4M | $222.8M | $185.4M | $130.6M | $332.3M | $278.8M | $918.7M |
| Cash flow | ||||||||
| Operating cash flow | −$17.2M | −$25.4M | −$29.4M | −$29.6M | −$29.6M | −$43.0M | −$42.6M | −$52.8M |
From Definium Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Definium Therapeutics Inc in our feed yet.